alpha labs retatrutide (RETA) – Research Peptide Retatrutide (GLP-3) Research Peptide |

Rare in the trials, but a recognised concern with GLP-1 medications generally, partly because rapid weight loss itself can trigger gallstones

However, selective NaV1.7 inhibitors have repeatedly failed in the clinic, and recent studies across multiple programs point to on-target autonomic and cardiovascular liabilities

The before and after results people share online typically reflect months of use at therapeutic doses, not the starting dose period

Changes in macronutrient ratios shift bacterial populations

Several groups have designed monomeric dual and triple agonists based on the interactions of GLP-1 with glucagon 54,55,56 and/or GIP 57,58,59

GLP-1 receptor agonists increase serotonin turnover in the brain, meaning more serotonin is being released, utilized, and recycled